title: CCR 20th anniversary commentary: a chimeric antibody, C225, inhibits EGFR activation and tumor growth.
abstract: Murine mAb 225 was effective against the EGFR tyrosine kinase and inhibited tumor growth in preclinical studies. A phase I trial showed safety, tumor localization, and satisfactory pharmacokinetics. Human:murine chimeric C225 retained biologic activity, which was essential for the conduct of subsequent combination therapy trials and eventual regulatory approval.
authors.affiliation: The University of Texas MD Anderson Cancer Center, Houston, Texas. jmendelsohn@mdanderson.org.
authors.forename: John
authors.initials: J
authors.lastname: Mendelsohn
authors.affiliation: Eli Lilly and Company, Indianapolis, Indiana.
authors.forename: Marie
authors.initials: M
authors.lastname: Prewett
authors.affiliation: Hunter College, City University of New York, New York, New York.
authors.forename: Patricia
authors.initials: P
authors.lastname: Rockwell
authors.affiliation: Helio Genetics, East Hanover, New Jersey.
authors.forename: Neil I
authors.initials: NI
authors.lastname: Goldstein
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000068818:Cetuximab; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C512478:EGFR protein, human; D066246:ErbB Receptors; D000068818:Cetuximab